Galectin-3 분자 정보
Molecule Name
Galectin-3
분자 별명
Galectin-3,LGALS3,MAC2,Gal-3,35 kDa lectin,CBP 35,GALBP,IgE-binding protein,L-31,Laminin-binding protein,Lectin L-29,Mac-2 antigen
Drug Development Progress
임상 약물 수7
시판 약물 수1
최고 연구 개발 단계Approved
표적 별명
Galactoside-binding protein，GALBP，Epididymis Secretory Sperm Binding Protein，MAC2，Laminin-binding protein，CBP 35，Gal-3，IgE-binding protein，Carbohydrate-binding protein 35，L-31，Lectin L-29，LGALS3，Advanced Glycation End-Product Receptor 3，Lectin， Galactoside-Binding， Soluble， 3，Galactose-Specific Lectin 3，35 KDa Lectin，Mac-2 Antigen，Galectin-3，LGALS2，CBP35，GALIG，GAL3，L31，Galectin 3，MAC-2
분자 배경
Galectin-3 (Gal-3) is also known as LGALS3, 35 kDa lectin, Carbohydrate-binding protein 35 (CBP 35), Galactose-specific lectin 3, Galactoside-binding protein (GALBP), IgE-binding protein, Laminin-binding protein, Mac-2 antigen, Lectin L-29. Galectin-3 is a member of the lectin family. LGALS3 / Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. LGALS3 / Galectin-3 has been shown to be involved in the following biological processes: cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis.
Galectin-3 제품 목록
You Have Viewed 0 Of 0 Results
임상 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Olitigaltin | GB-0139; TD-139 | Phase 2 Clinical | Lund University Foundation, The University Of Edinburgh | Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis | 상세 |
| Galactomannan C | GM-CT-01 | Phase 2 Clinical | Galectin Therapeutics Inc | Bile Duct Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Gallbladder Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Prostatic Neoplasms | 상세 |
| Selvigaltin | GB-1211; GB1211 | Phase 2 Clinical | Galecto Inc | Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck | 상세 |
| ProLectin-M | Phase 2 Clinical | BioXyTran Inc | Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Influenza, Human | 상세 | |
| Gal-400 | Gal-400 | Phase 1 Clinical | Galecto Inc | Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease | 상세 |
| Belapectin | GR-MD-02 | Phase 1 Clinical | Galectin Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Esophageal and Gastric Varices; Hepatic Insufficiency; Hypertension, Portal; Liver Cirrhosis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Psoriasis; Squamous Cell Carcinoma of Head and Neck | 상세 |
| SIF-001 | SIF001 | Phase 1 Clinical | Suninflam Inc | Epilepsy; Neuroinflammatory Diseases | 상세 |
시판 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ocriplasmin | A-01016; THR-409 | Approved | Thrombogenics | Jetrea, Jejetrea | United States | Vitreomacular Adhesion | Thrombogenics Inc | 2012-10-17 | Arterial Occlusive Diseases; Diabetic macular oedema; Diabetic Retinopathy; Disease Progression; Eye Diseases; Macular Degeneration; Retinal Diseases; Retinal Vein Occlusion; Stroke; Uveitis; Venous Thrombosis; Vitreomacular Adhesion; Vitreous Detachment | 상세 |